Sedative-Hypnotic Effects of Glycine max Merr. Extract and Its Active Ingredient Genistein on Electric-Shock-Induced Sleep Disturbances in Rats.
Study Design
- Studientyp
- animal experimental study
- Intervention
- Sedative-Hypnotic Effects of Glycine max Merr. Extract and Its Active Ingredient Genistein on Electric-Shock-Induced Sleep Disturbances in Rats. GM 400 mg/kg; GE 30 mg/kg
- Vergleichsgruppe
- Placebo
- Wirkungsrichtung
- Positive
- Verzerrungsrisiko
- Moderate
Abstract
Glycine max Merr. (GM) is a functional food that provides many beneficial phytochemicals. However, scientific evidence of its antidepressive and sedative activities is scarce. The present study was designed to investigate the antidepressive and calmative effects of GM and its biologically active compound, genistein (GE), using electroencephalography (EEG) analysis in an electric foot shock (EFS)-stressed rat. The underlying neural mechanisms of their beneficial effects were determined by assessing corticotropin-releasing factor (CRF), serotonin (5-HT), and c-Fos immunoreactivity in the brain using immunohistochemical methods. In addition, the 5-HT2C receptor binding assay was performed because it is considered a major target of antidepressants and sleep aids. In the binding assay, GM displayed binding affinity to the 5-HT2C receptor (IC50 value of 14.25 ± 11.02 µg/mL). GE exhibited concentration-dependent binding affinity, resulting in the binding of GE to the 5-HT2C receptor (IC50, 77.28 ± 26.57 mg/mL). Administration of GM (400 mg/kg) increased non-rapid eye movement (NREM) sleep time. Administration of GE (30 mg/kg) decreased wake time and increased rapid eye movement (REM) and NREM sleep in EPS-stressed rats. In addition, treatment with GM and GE significantly decreased c-Fos and CRF expression in the paraventricular nucleus (PVN) and increased 5-HT levels in the dorsal raphe in the brain. Overall, these results suggest that GM and GE have antidepressant-like effects and are effective in sleep maintenance. These results will benefit researchers in developing alternatives to decrease depression and prevent sleep disorders.
Full Text
Figures
Figure 1
Experimental design or animal behavioral data from a study on the sedative-hypnotic effects of Glycine max (soybean) extract and its active ingredient isoflavones.
chart
Figure 2
Sleep onset latency or total sleep time measurements in animals treated with Glycine max extract, comparing different doses to positive controls.
chart
Figure 3
Electroencephalographic (EEG) or sleep architecture data from the Glycine max sedative-hypnotic study, characterizing effects on sleep stages.
chart
Figure 4
Neurotransmitter level analysis (GABA, serotonin, or related) in brain regions of animals treated with Glycine max extract.
chart
Figure 5
Receptor binding or molecular mechanism data explaining the sedative-hypnotic activity of soybean-derived isoflavones.
chart
Figure 6
Dose-response or safety profile data for Glycine max extract as a potential sleep-promoting supplement.
chartReferences
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
British journal of pharmacology · 2006
GABA and glycine as neurotransmitters: a brief history.
Human mutation · 2009
A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation.
Electronic physician · 2017
A review of effective herbal medicines in controlling menopausal symptoms.
Sleep medicine reviews · 2017
Not a single but multiple populations of GABAergic neurons control sleep.
Nutritional neuroscience · 2008
Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2018